Federal Register
Potency Assurance for Cellular and Gene Therapy Products; Guidance for Industry; Availability- Facts included
- The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Potency Assurance for Cellular and Gene Therapy Products."
- The guidance document provides recommendations to help assure the potency of human cellular therapy or gene therapy (CGT) products at all stages of the product lifecycle.
- FDA is recommending a comprehensive approach to potency assurance of CGT products that is grounded in quality risk management.
- For investigational products, the guidance describes how to progressively implement a strategy for potency assurance during product development and provides additional considerations for rapidly developing products.
- For licensed products, the guidance describes requirements for potency assurance, including testing required for lot release assays.
- Sourcing
- High – the information originates directly from an FDA announcement and includes specific details about the guidance document.
- Framing
- The text is purely informational and does not contain opinion; it reports the FDA's announcement and outlines the content of the guidance.
- Omissions
- The excerpt does not provide information on how the guidance will be implemented by industry, any timelines for compliance, potential challenges for manufacturers, or the expected impact on product approval processes.
- Rhetorical notes (3)
- Authority Appeal · Technical Language · Future Orientation